HAVAS partners with WebMD on "Virtual Convention Booth"

Share this article:
HAVAS partners with WebMD on "Virtual Convention Booth"
HAVAS partners with WebMD on "Virtual Convention Booth"
Euro RSCG Life parent HAVAS is partnering with WebMD for a new Virtual Convention Booth offering that aims to give healthcare professionals the 3D interactive experience online.

The Virtual Convention Booth is the first offering from a new HAVAS agency, HAVAS Drive, specializing in the design of virtual environments for patients and professionals. The shop, based in New York and with quality assurance staff in Portland, OR, is launching with a staff of 15 and several products that will offer pay-for-performance pricing. In addition to the Virtual Convention Booth, to be hosted on WebMD's Medscape using content supplied by clients. 

HAVAS Drive is also offering Virtual Detail, which allows a virtual sales rep to deliver a detail in a 3-D environment live or remotely, via the web or CD-ROM, and Virtual Hospital, an educational tool aimed at helping hospital staff optimize patient care through simulations drawn from case studies of real patients' experiences, from admission to discharge.

HAVAS Drive hopes Virtual Detail will appeal to companies looking to launch a product quickly, reach physicians in areas where they don't have coverage or disseminate new data fast.

The agency is also working on Virtual Patient, a consumer- and professional-facing application aimed at helping both audiences understand what a typical patient with a particular disease goes through on a daily basis. “We want to close the information gap between the physician and the patient,” said Ed Stapor, a partner at Euro RSCG Life who is leading the new shop.

Stapor said HAVAS has signed up clients for six Virtual Details, two Virtual Hospitals and one Virtual Convention Booth. All of the agency's products will offer performance-based pricing. “We will work with clients to define what metrics they are looking for, and then, that's how we'll get paid – per engagement, so that there's skin in the game for us,” said Stapor. Clients will also pay a licensing fee up front.  
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...